Review Article
N-Acetyl Cysteine as an Adjunct in the Treatment of Tuberculosis
Table 3
List of studies on the hepatoprotective effect NAC on anti-TB drugs.
| | Author | Year | Type of study | Types of animals or cells | Dose or concentration of NAC | Type of anti-TB | Protection by NAC | Reference |
| | Attri et al. | 2000 | Animal study | Wistar rats | 100 mg/kg | INH (50 mg/kg), RIF (50 mg/kg) | Yes | [83] | | Rana et al. | 2006 | Animal study | Wistar rats | 100 mg/kg | RIF (50 mg/kg) | Yes | [82] | | Singh et al. | 2012 | In vitro | HepG2 | 10 μM | INH (100, 200 mM), RIF (50 mM), PZA (100, 200 mM) | Yes | [86] | | Baniasadi et al. | 2011 | Clinical trial | NA | 600 mg PO BID | INH, RIF, PZA, ETH | Yes | [87] |
|
|
NAC: N-acetyl cysteine; INH: isoniazid; RIF: rifampicin; PZA: pyrazinamide; hepG2: human liver cancer cell line.
|
